DK0807124T3 - Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi - Google Patents

Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi

Info

Publication number
DK0807124T3
DK0807124T3 DK95922533T DK95922533T DK0807124T3 DK 0807124 T3 DK0807124 T3 DK 0807124T3 DK 95922533 T DK95922533 T DK 95922533T DK 95922533 T DK95922533 T DK 95922533T DK 0807124 T3 DK0807124 T3 DK 0807124T3
Authority
DK
Denmark
Prior art keywords
diagnosis
therapy
monoclonal antibody
tyrosine kinase
antibody against
Prior art date
Application number
DK95922533T
Other languages
English (en)
Inventor
Kari Alitalo
Paeivi Karnani
Arja Kaipainen
Jaana Korhonen
Tuija Mustonen
Katri Pajusola
Marja-Terttu Matikainen
Original Assignee
Licentia Oy
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Oy, Ludwig Inst Cancer Res filed Critical Licentia Oy
Application granted granted Critical
Publication of DK0807124T3 publication Critical patent/DK0807124T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK95922533T 1994-06-09 1995-06-09 Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi DK0807124T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25775494A 1994-06-09 1994-06-09

Publications (1)

Publication Number Publication Date
DK0807124T3 true DK0807124T3 (da) 2006-08-28

Family

ID=22977612

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95922533T DK0807124T3 (da) 1994-06-09 1995-06-09 Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi

Country Status (14)

Country Link
EP (1) EP0807124B1 (da)
JP (4) JP3723210B2 (da)
AT (1) ATE326484T1 (da)
AU (1) AU694524B2 (da)
CA (1) CA2192235C (da)
DE (1) DE69534996T2 (da)
DK (1) DK0807124T3 (da)
ES (1) ES2263152T3 (da)
FI (1) FI964862A (da)
MX (1) MX9606218A (da)
NO (1) NO319383B1 (da)
NZ (1) NZ288235A (da)
PT (1) PT807124E (da)
WO (1) WO1995033772A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
EP1353952B1 (en) * 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
AU774266B2 (en) * 1998-10-09 2004-06-24 Vegenics Limited Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CA2370237A1 (en) * 1999-04-13 2000-10-19 Northwest Biotherapeutics, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
EP1553414A1 (en) * 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6599717B1 (en) * 1999-10-01 2003-07-29 Exelixis, Inc. Invertebrate vascular endothelial growth factor receptor
WO2007138143A2 (es) * 2006-05-29 2007-12-06 Consejo Superior De Investigaciones Cientificas Anticuerpos monoclonales anti-colina quinasa alfa y su uso en técnicas analíticas, de diagnóstico del cáncer y en la preparación de medicamentos
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
EP3693381A1 (en) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligand binding molecules and uses thereof
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014124A1 (en) * 1992-01-09 1993-07-22 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase
DE69233739D1 (de) * 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF

Also Published As

Publication number Publication date
NO965231D0 (no) 1996-12-06
FI964862A0 (fi) 1996-12-04
JPH10500858A (ja) 1998-01-27
DE69534996T2 (de) 2007-05-10
JP2005139199A (ja) 2005-06-02
PT807124E (pt) 2006-08-31
EP0807124A1 (en) 1997-11-19
FI964862A (fi) 1997-02-10
MX9606218A (es) 1998-02-28
EP0807124B1 (en) 2006-05-17
JP3723210B2 (ja) 2005-12-07
DE69534996D1 (de) 2006-06-22
WO1995033772A1 (en) 1995-12-14
NO965231L (no) 1996-12-06
CA2192235A1 (en) 1995-12-14
JP2009102415A (ja) 2009-05-14
AU694524B2 (en) 1998-07-23
ES2263152T3 (es) 2006-12-01
NO319383B1 (no) 2005-07-25
CA2192235C (en) 2011-02-15
JP2012193191A (ja) 2012-10-11
ATE326484T1 (de) 2006-06-15
AU2738895A (en) 1996-01-04
NZ288235A (en) 1999-05-28

Similar Documents

Publication Publication Date Title
DK0807124T3 (da) Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi
DK0540573T4 (da) Assay for frit- og kompleksbundet prostataspecifikt antigen (PSA)
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
NO974534D0 (no) Bestemmelse av cPSA
BR0111731A (pt) Ensaio de combinação de anticorpo/antìgeno do hcv
SE8701905L (sv) Foerfarande och kit foer diagnos av iga-nefropati
CA2361000A1 (en) Urinary trypsin inhibitor to diagnose aids
NO177463C (no) STLV-III-beslektede polypeptider, diagnostiske prövesett og in vitro analysefremgangsmåte for påvisning av anti-HIV-2-antistoffer i kroppsvæskepröve
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
ATE433575T1 (de) Neurotransmission-störungen
ES2189254T3 (es) Dosificado inmunologico que permite detectar los anticuerpos igm especificos del citomegalovirus humano.
FI943921A0 (fi) Bestaemning av fri och komplexbunden trypsinogen-2
ES2075803A1 (es) Procedimiento de la deteccion de neumolisina
WO1990008956A1 (fr) Detection d'activateur de facteur tissulaire humain
IT1309442B1 (it) Procedimento di rivelazione immunoenzimatica di un complesso antigene/anticorpo primario e kit diagnostico per la sua attuazione.
RU2000127064A (ru) Способ диагностики развития дегенеративно-дистрофических поражений позвоночника у детей